 This European Amatology Association of Virtual Congress highlighted relevant news in multiple myeloma. In the Afro setting, while in the management of maybe the diagnosed myeloma patients, we had the opportunity to see some data coming from new trials conducted, for example, in patients with a high risk, high risk-high genetic abnormalities. And this is the case for Bortesomibylenalytomide and dexamethasone, plus the monoclonal antibody, iletusumabate. And surprisingly, iletusumabate is not able to overcome the prognosis of the presence of high risk, high genetic abnormalities. Another study also conducted in a high risk, in patients with myeloma patients with high risk evaluated the role of carfilosamine, the second generation proteasin inhibitor in combination with iletusumabate and dexamethasone, and iletusumabate, the undecinatory age monoclonal antibody. And although the sample size is rather small right now, the results were quite promising and maybe this quadruple combination can potentially overcome the good prognosis of the presence of high risk, cytogenetic abnormalities. In the treatment of the unit, I have known myeloma patients, but in the elderly population, not eligible for auto-resistence and transplantation, we had some data about dexamethasone, the old proproteasin inhibitor evaluated as maintenance, so after whatever induction, based on proteasin inhibitor in need or PI plus in need, patients were randomized to receive dexamethasone as proteasin inhibitor of oral administration versus placebo. And the trial met its primary endpoint, meaning that dexamethasone was maintenance for longer than the progression to survival in comparison with placebo. And from my personal point of view, I think that this is an excellent opportunity to extend the duration of the response in this population through the proteasin inhibition with dexamethasone, and also this drug opens the door to be combined with the monoclonal antibodies or immunomodulatory drugs. Even if we move to the relaxing refractory setting, in every relaxation, we have a well-aligned, breaking-up strata presented by Professor Moro from Nantes based on a new combination, perfusion of dexamethasone plus the monoclonal antibody isatuximum evaluated in the phase three randomized trial, the control arm of also perfusion of dexamethasone. Patients included in this study were relaxed and refractory myeloma patients after one to three prior lines of therapy. And the addition of isatuximum and perfusion of dexamethasone resulted in less significant benefit in terms of progression to survival with a hazard ratio of 0.5. And this benefit was sustained across the difference group of patients. Also important to remark the high overall response rate, almost 90%, with a complete response rate for patient-perceived perfusion of dexamethasone and isatuximum over 30%, with a quite significant proportion of patients achieving minimal residual disease therapy. And the toxicity profile was also quite acceptable. And this means that perfusion of dexamethasone plus isatuximum will be made a new standard of care for relaxed and refractory myeloma patients. In this same population, the Boston study showed the positive results also for a new combination, serinexor and oral drug inhibiting the exporting of one in combination with dexamethasone. And this combination prolonged also the process of survival in comparison with dexamethasone alone and the benefit was quite sustained across the difference group of patients, especially patients with initial 70B and definitely this trial also put in context how this drug can be evaluated in patients with this cytogenetic abnormality. But the benefit was also quite evident in other patients over the 65 years as well as those patients treated with immunomodulatory drugs after the first line of therapy. So this is another phase, the mice trial that has been presented at AHA and I would like to remind you here. And if we move to later on the stage of the disease, so patients in third line and beyond, some of the analysis based on dexamethasone or dexamethasone plus isatuximum have been presented, but I would like to highlight the monoclonal antibody started in BCMA, because this is something new and different updates starting from the cultivated monoclonal antibody, Bell and Muff from our photo team. And I would like to highlight the higher efficacy so far reported when this monoclonal antibody has been combined with dexamethasone or dexamethasone. As well as some sub-analysis reported in patients with some degree of renal internment or high receptor genetic abnormalities. And following that, when BCMA has started, we had the opportunity to see some abstracts with T-cell engager, so by specific monoclonal antibodies started in BCMA. In the end, we recruited myeloma patients with encuraging results. Finally I would like to highlight the parties started in BCMA, the karma pre-bottom trial as well as the evolved trial and the articulated trial. And these three clinical trials have been conducted in patients with myeloma after at least five or six prior likes of therapy and significant proportion of patients presented with extramedular diseases and high tumor gotten. And definitely the overall risk of grave with a complete response rate. The minimal disease negative rate has been received from my point of view for all of them. If we consider that the population included in this study will result in an overall response rate of 30% with conventional agents. And in this trial, we had the opportunity to see overall response rate over 80% in all of them with a complete response rate ranging from 30% up to 45%. So these results are impressive. The only problem is the duration of the response because after CAR-T, the durability of the response is not very long and this is something in which we have to continue to investigate in order to extend the durability of the response previously achieved. From the same point of view, CAR-T is shown to be manageable with the cytokine release syndrome occurring in almost all patients as well as a neurological toxicity in some patients and the hematological toxicity. But definitely I think that this European hematology association to our progress put in context how many new combinations are emerging for the management of relax and retractable myeloma patients and also how these combinations can move earlier on even in the Afron setting and definitely this is going to contribute to improve the overall survival of our patients with what we call myeloma. The crystal map is a bi-specific to a body monoclonal antibody targeted in BCMA but at the same time it radiates T lymphocytes to the tumor niche so this means that this bi-specific monoclonal antibody is going to induce the cytotoxicity through the activation of the T lymphocytes. The T-stamava has been evaluated in a series of 76 relax and retractable myeloma patients after at least 6 prior lines of therapy 84% of the patients were 3-drug classical fracturing meaning that they were fracturing proteasomy hematodes monomodulatory drugs and anti-CD38 monoclonal antibodies and a significant proportion of patients have the extramedular disease as well as high risk to detect anomalies. This is a phase one study meaning that patients were included in different cohorts receiving different doses. Efficacy was dose dependent and we concentrated on the group of patients receiving for receiving the highest dose so far reported the overall response rate was approximately 70% with more than 50% of the patients achieving VGPR. In addition, some patients have quite a significant proportion of patients who responded were 3-drug classical fracturing and in fact some of them were even 10-drug fracturing. Some patients even achieving complete response achieved the minimum of disease negative, what is important. The follow-up is quite short right now so the response of media permission for survival has not been reached yet and there is an additional cohort of patients that have been treated now receiving a higher dose in micrograms per kilo and they are not much together this put in context that these efficacy results are preliminary and maybe they can be better when these new cohorts of patients have mature results. This Ceremonogram antibody today is given of IV administration but important to note that the SAC2 administration is being also evaluated in some patients so maybe the final group of administration can be SAC2, what is much more convenient for patients. From the safety point of view as this is a bite-specific monoclonal antibody redirecting these cells to the tumor needs, these still infocytes are going to be activated meaning that Cytopurus syndrome is a potential adverse event that occurred in 56% of the patients but in all of them it was only the day one and two and no patient developed a great free cytokine release syndrome. The hematological toxicity also were reported the day three, four, neutropenia or thrombocytopenia in approximately one third of the patients although the frequency of infection is quite low approximately 90% of the patients and some patients also developed a neurotoxicity always following cytokine release syndrome but it resulted in almost all patients so I would say that if we put efficacy and safety together I think that the results over to Cristama in this first human phase one clinical trial are encouraging because safety profile is acceptable efficacy is quite encouraging, some patients continue on going in the trial and the clinical development is going and definitely I think that Cristama as a for other diesel endangers or bi-specific monoclonal antibodies will be incorporated to the treatment landscape of our patients with multiple myeloma yes, there are other bi-specific monoclonal antibodies in the future target in BCMA but the clinical development for this new approach of therapy is very exciting because there are some even bi-specific but even three specific monoclonal antibodies that will be not only BCMA but maybe since the 30 age and together the three lymphocytes in order to bring these lymphocytes to the cure so definitely I think that the clinical development plan for this endangers is very exciting the endangers are these as well as the monoclonal antibodies the contributed monoclonal antibodies like to balance the amount of all of them are targeted in BCMA and well the one appropriate question is how patients are going to proceed in order to choice CAR-T versus endangers versus contributed monoclonal antibodies and I think that this is related to the factors as well as patient related factors have to be considered in order to make the right choice CAR-Ts are very attractive but also patients need to wait approximately 6 up to 7 weeks between the selection of the patient for CAR-T and the moment in which the patient finally received the CAR-T because the lymphocytes have to be modified and this required approximately 4-5 weeks these endangers or by specific monoclonal antibodies or monoclonal antibodies but also travels as well as patients' preferences as well as hospital survivability have to be considered but definitely I think that the patients are going to be in the pharmacy of the hospital and maybe some patients with a very aggressive relax can wait to be CAR-T and it is possible to select or but definitely I think that the BCMA is a target that make me all patients with monoclonal myeloma will receive maybe through dysselegia here by specific monoclonal antibodies conjugated monoclonal antibodies or CAR-Ts but BCMA monoclonal antibodies or BCMA targeted therapy will take part of the treatment of almost all patients in the hospital and it is possible to take part in the treatment of patients with monoclonal antibodies or CAR-Ts or CAR-Ts or CAR-Ts or CAR-Ts or CAR-Ts or CAR-Ts or CAR-Ts or CAR-Ts or CAR-Ts